News
Celeris Therapeutics to receive 12.5 million Euros in funding from the European Innovation Council
EINPressWire – October 19, 2022
Celeris Therapeutics, the pioneer in AI-driven degrader design, today announces funding from the European Innovation Council (EIC).
CelerisTx Announces Key Management Promotion
EINPressWire – June 14, 2022
CelerisTx Reels in Another Big Partner in Boehringer Ingelheim
BioSpace® – April 05, 2022
CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors
BioSpace® – February 25, 2022
CelerisTx announces $4.4m financing to advance pipeline of novel proximity inducing compound
BioSpace® – February 10, 2022
Merck KGaA enlists little AI player on protein degrader discovery
Endpts – February 09, 2022
CelerisTx in Artificial Intelligence research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled degrader discovery
BioSpace® – February 09, 2022
Celeris Therapeutics, the PIC™ engineering company, announces the appointment of biotech veterans to lead drug discovery and biology efforts
BioSpace® – February 02, 2022
The hirings of Dr. Friedrich Kroll, who is joining as VP Drug Discovery, and Dr. Markus Muellner joining as VP Biology, reflect the ambition to get into the clinic fast.
Celeris Therapeutics, Inc., pioneering AI-driven degrader discovery, appoints Nick DeHaan as VP, Head of Partnering
EINPresswire – November 29, 2021
Silicon Valley-based startup recruits experienced business development leader to drive growth in AI-based protein degrader discovery partnerships
Celeris Therapeutics, the Pioneer in AI-driven Degrader Design, Builds Laboratories in Austria
EINPresswire – November 01, 2021
Adds ~25 new jobs, building on 20 created in 2021. Increases capacity and efficiency of AI-based drug discovery capabilities in chemistry and biology.
Celeris Therapeutics Welcomes Life Sciences and Technology Thought Leader Ian Marks as a Non-Executive Director
EINPresswire – August 27, 2021
Global VP of Life Sciences at Salesforce contributes a great deal of experience in life sciences, pharma and technology
Rational design for protein degradation? Austrian deep learning startup takes a stab
Endpoints – July 19, 2021
Rational design for protein degradation? Austrian deep learning startup takes a stab
600.000 Euro für Grazer Startup Celeris
Der Brutkasten – May 3, 2021
Knapp nach einem 400.000 Euro Seed-Investment holt sich Celeris aus Graz eine aws-Förderung für seine Medikamentenforschungstechnologie.
Cutting longevity drugs development from 15 years to on
Noah Weber – March 31, 2021
Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer’s and other age-related diseases.
Accelerating drug discovery through artificial intelligence would help to bring longevity innovations to the clinic more quickly.
Lifespan.io – April 06, 2021
We all know that technology is rapidly improving and changing how we live. But we’re going to need even more technological breakthroughs to improve human maximum healthspan and lifespan. Can a new start-up cut longevity drugs development from 15 years to one?
Grazer Biotech-Startup erhält 400.000 Euro Pre-Seed-Investment
Der Brutkasten – March 31, 2021
Celeris Therapeutics will mit seiner Plattform ermöglichen, dass bessere Medikamente schneller auf den Markt kommen – und konnte damit internationale Investoren überzeugen.
Durch künstliche Intelligenz zum perfekten Medikament
CHEManager – January 26, 2021
Eine Deep-Learning-Plattform für medizinische Chemiker zur schnelleren und genaueren Vorhersage von Bindungsaffinitäten und daraus resultierendem Design von Arzneimitteln – das will das Start-up Celeris Therapeutics aus Graz noch dieses Jahr zur Marktreife entwickeln.
